Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA
FREMONT, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company...